What is evidence-based, what is new in medical therapy of acute heart failure?

Herz

Volumn 31, Issue 8, 2006, Pages 771-779

  Grimm, Wolfram ^a,b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Acute heart failure; Medical therapy

Indexed keywords

5 MONO NITRATE; ADRENALIN; BUMETANIDE; CARDIAC GLYCOSIDE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; MORPHINE; NESIRITIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; RECOMBINANT HORMONE; RECOMBINANT HUMAN BRAIN PEPTIDE; SPIRONOLACTONE; TEZOSENTAN; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; ANTICOAGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; EVIDENCE BASED MEDICINE; FOLLOW UP; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; META ANALYSIS; OXYGEN SUPPLY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; QUESTIONNAIRE; RESTLESSNESS; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TOXICITY; VENTILATOR;

ANTI-ARRHYTHMIA AGENTS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CLINICAL TRIALS; EUROPE; EVIDENCE-BASED MEDICINE; FORECASTING; HEART-ASSIST DEVICES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; VASODILATOR AGENTS;

EID: 33845596054     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2910-y     Document Type: Review

References (30)

1. Nieminen MS, Bohm M, Cowie MR, et al., ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
2. Zannad F, Mebazaa A, Juilliere Y, et al., for the EFICA Investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 2006;8:697-705.
3. Swedberg K, Cleland J, Dargie H, et al., Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
4. Fonarow GC, Corday E, ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004;3:179-85.
5. Dickstein K. Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. Eur J Heart Fail 2005;7:303-8.
6. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9.
7. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9.
8. DIG Trial, the Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
9. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
10. Pitt B, Remme W, Zannad F, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
11. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93.
12. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
13. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-5.
14. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005;96:59G-67G.
15. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5.
16. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
17. Hodt A, Steine K, Atar D. Medical and ventilatory treatment of acute heart failure: new insights. Cardiology 2006;106:1-9.
18. Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 2003;91:245-8.
19. Teerlink JR, McMurray JJ, Bourge RC, et al., for the VERITAS Investigators.Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46-53.
20. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91.
21. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
22. Gheorghiade M, Gattis WA, O'Connor CM, et al., Acute and ChronicTherapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71.
23. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005;11:260-9.
24. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G.
25. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail 2002;4:515-29.
26. Follath F, Cleland JG, Just H, et al., for the Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
27. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. EurJ Heart Fail 2004;6:501-8.
28. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.
29. Cuffe MS, Califf RM, Adams KF Jr, et al., Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
30. Spargias KS, Hall AS, Ball SG. Safety concerns about digoxin after acute myocardial infarction. Lancet 1999;354:391-2.